Clinuvel Pharmaceuticals Debt 2024

Clinuvel Pharmaceuticals Aktienanalyse

What does Clinuvel Pharmaceuticals do?

Clinuvel Pharmaceuticals Ltd is a biopharmaceutical company that specializes in researching, developing, and marketing drugs targeting skin pigmentation. The company was founded in 1987 and is headquartered in Melbourne, Australia. It has become a leading expert in the field of light and pigment medicine since its establishment. Clinuvel's business model focuses on utilizing innovative technologies and scientific research to develop new products and therapies that benefit patients worldwide. The company specializes in developing safe and effective drugs based on research in therapeutic areas such as skin pigment disorders and skin cancer prevention. In recent years, the company has expanded its various divisions to meet market demand and extend innovations to other areas of medicine. Clinuvel's main divisions are Pharmaceuticals and Nutraceuticals. Clinuvel's pharmaceutical division specializes in developing new drugs and therapies for modulating skin pigmentation. The company is particularly known for its flagship product, SCENESSE, an implant that allows people with the rare condition erythropoietic protoporphyria (EPP) to live without pain in the sun. SCENESSE has received European and Australian approvals and is prescribed worldwide by a growing network of treatment centers. Clinuvel's nutraceutical division focuses on developing dietary supplements and advising patients who want to improve their skin from within. This includes products like Cuvita, a dietary supplement containing antioxidants and other nutrients that can contribute to the health of hair, skin, and nails. Clinuvel has expanded its business models to meet the needs of patients in different regions of the world. For example, the company has developed a comprehensive integration strategy in Europe to promote research, development, and marketing of innovative products and therapies. Overall, Clinuvel Pharmaceuticals is a company that focuses on developing innovative drugs and therapies in the field of light and pigment medicine. It is known for its advanced research, successful development of SCENESSE, and commitment to patients worldwide. It will be interesting to see how the divisions develop in the future, but innovative drugs and therapies are definitely an important part of Clinuvel's future. Clinuvel Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Clinuvel Pharmaceuticals's Debt Structure

Clinuvel Pharmaceuticals's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Clinuvel Pharmaceuticals's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Clinuvel Pharmaceuticals’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Clinuvel Pharmaceuticals’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Clinuvel Pharmaceuticals stock

What is the debt of Clinuvel Pharmaceuticals this year?

Clinuvel Pharmaceuticals has a debt level of -17.22 AUD this year.

What was the debt of Clinuvel Pharmaceuticals compared to the previous year?

The debt of Clinuvel Pharmaceuticals has increased by -87.96% compared to the previous year dropped.

What are the consequences of high debt for investors in Clinuvel Pharmaceuticals?

High debt can pose a risk for investors of Clinuvel Pharmaceuticals, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Clinuvel Pharmaceuticals?

Low debt means that Clinuvel Pharmaceuticals has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Clinuvel Pharmaceuticals affect the company?

An increase in debt of Clinuvel Pharmaceuticals can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Clinuvel Pharmaceuticals affect the company?

A reduction in debt of Clinuvel Pharmaceuticals can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Clinuvel Pharmaceuticals?

Some factors that can influence the debt of Clinuvel Pharmaceuticals include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Clinuvel Pharmaceuticals so important for investors?

The debts of Clinuvel Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Clinuvel Pharmaceuticals take to change the debt?

To change the debt, Clinuvel Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Clinuvel Pharmaceuticals pay?

Over the past 12 months, Clinuvel Pharmaceuticals paid a dividend of 0.07 AUD . This corresponds to a dividend yield of about 0.5 %. For the coming 12 months, Clinuvel Pharmaceuticals is expected to pay a dividend of 0.08 AUD.

What is the dividend yield of Clinuvel Pharmaceuticals?

The current dividend yield of Clinuvel Pharmaceuticals is 0.5 %.

When does Clinuvel Pharmaceuticals pay dividends?

Clinuvel Pharmaceuticals pays a quarterly dividend. This is distributed in the months of October, October, October, October.

How secure is the dividend of Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals paid dividends every year for the past 13 years.

What is the dividend of Clinuvel Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0.08 AUD are expected. This corresponds to a dividend yield of 0.57 %.

In which sector is Clinuvel Pharmaceuticals located?

Clinuvel Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Clinuvel Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Clinuvel Pharmaceuticals from 9/20/2024 amounting to 0.071 AUD, you needed to have the stock in your portfolio before the ex-date on 9/5/2024.

When did Clinuvel Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/20/2024.

What was the dividend of Clinuvel Pharmaceuticals in the year 2023?

In the year 2023, Clinuvel Pharmaceuticals distributed 0.071 AUD as dividends.

In which currency does Clinuvel Pharmaceuticals pay out the dividend?

The dividends of Clinuvel Pharmaceuticals are distributed in AUD.